SCHEMBL12371283

SCHEMBL12371283

COc1cc2cc(c1Cl)N(C)C(=O)C[C@H](OC(=O)[C@@H](C)N(C)C(=O)CCSC(C)C)[C@]1(C)O[C@H]1[C@H](C)[C@@H]1C[C@@](O)(NC(=O)O1)[C@H](OC)/C=C/C=C(\C)C2

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB4A P04350 4/20 0.84
TUBB P07437 4/20 0.84
TUBA3C P0DPH7 4/20 0.84
TUBA1B P68363 4/20 0.84
TUBA4A P68366 4/20 0.84
TUBB4B P68371 4/20 0.84
TUBB3 Q13509 4/20 0.84
TUBB2A Q13885 4/20 0.84
TUBB8 Q3ZCM7 4/20 0.84
TUBA3E Q6PEY2 4/20 0.84
TUBA1A Q71U36 4/20 0.84
TUBA1C Q9BQE3 4/20 0.84
TUBB6 Q9BUF5 4/20 0.84
TUBB2B Q9BVA1 4/20 0.84
TUBB1 Q9H4B7 4/20 0.84
CYP2D6 P10635 1/20 0.79
TSHR P16473 1/20 0.79
CYP2C19 P33261 1/20 0.79
HIF1A Q16665 1/20 0.79
P4HB P07237 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18389685 1.00 TUBB4A (0.84) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL26212394 1.00 TUBB4A (0.84) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL836373 1.00 TUBB4A (0.84) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL14669823 1.00 TUBB4A (0.84) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL19601281 1.00 TUBB4A (0.84) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL17213337 0.96 TUBB4A (0.86) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL23193005 0.96 TUBB4A (0.82) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL835527 0.96 TUBB4A (0.85) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL12371281 0.96 TUBB4A (0.85) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL835433 0.96 TUBB4A (0.85) TUBB4ATUBBTUBA3CTUBA1BTUBA4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239885-A1 ANTIBODY CONJUGATE COMPRISING ANTI-P-CADHERIN ANTIBODY AND USES THEREOF WuXi Biologics Ireland Limited (IE) 2024-07-18 US disclosed
US-8524865-B2 Antibodies and immunoconjugates and uses therefor GENENTECH, INC. (US) 2013-09-03 US disclosed
US-8436147-B2 Antibodies and immunoconjugates and uses therefor GENENTECH, INC. (US) 2013-05-07 US disclosed
US-7989434-B2 Heterocyclic self-immolative linkers and conjugates SEATTLE GENETICS, INC. (US) 2011-08-02 US disclosed
US-20100278842-A1 ANTI-EPHB2 ANTIBODIES AND METHODS USING SAME GENENTECH, INC. (US) 2010-11-04 US disclosed
US-20100273843-A1 HETEROCYCLIC SELF-IMMOLATIVE LINKERS AND CONJUGATES SEAGEN INC. 2010-10-28 US disclosed
US-7767205-B2 Anti-EphB2 antibodies and methods using same GENENTECH, INC. (US) 2010-08-03 US disclosed
US-20090280056-A1 Antibodies and immunoconjugates and uses therefor GENENTECH, INC. 2009-11-12 US disclosed
US-7521541-B2 A free cysteine amino acid is a cysteine residue which has been engineered into the parent antibody and is not part of a disulfide bridge; diagnostics and therapeutics; killing or inhibiting the proliferation of tumor cells or cancer cells GENETECH INC. (US) 2009-04-21 US disclosed
US-20090068178-A1 Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin GENENTECH, INC. (US) 2009-03-12 US disclosed
US-20080254024-A1 ANTI-EPHB2 ANTIBODIES AND METHODS USING SAME GENENTECH, INC. (US) 2008-10-16 US disclosed
US-7375078-B2 Heterocyclic self-immolative linkers and conjugates GENENTECH, INC. (US) 2008-05-20 US disclosed
US-20080050310-A1 ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR GENENTECH, INC. (US) 2008-02-28 US disclosed
US-20070092940-A1 A free cysteine amino acid is a cysteine residue which has been engineered into the parent antibody and is not part of a disulfide bridge; diagnostics and therapeutics; killing or inhibiting the proliferation of tumor cells or cancer cells GENENTECH, INC. (US) 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090280056-A1 Antibodies and immunoconjugates and uses therefor STXBP1, WASF2, SDAD1 TUBB4A 1373/4885TUBB 1457/4885TUBA3C 1328/4885
US-20100278842-A1 ANTI-EPHB2 ANTIBODIES AND METHODS USING SAME EPHB2, EPHB3, EPHB1 TUBB4A 104/4885TUBB 61/4885TUBA3C 123/4885
US-20090068178-A1 Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin HCLS1, CD47, MCL1 TUBB4A 397/4885TUBB 550/4885TUBA3C 484/4885
US-20240239885-A1 ANTIBODY CONJUGATE COMPRISING ANTI-P-CADHERIN ANTIBODY AND USES THEREOF CDH1, EPCAM, VIM TUBB4A 226/4885TUBB 313/4885TUBA3C 198/4885
US-20080050310-A1 ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR CD22, CD2BP2, CD2 TUBB4A 1843/4885TUBB 1954/4885TUBA3C 1536/4885
US-20100273843-A1 HETEROCYCLIC SELF-IMMOLATIVE LINKERS AND CONJUGATES CTSL, DNPEP, CTSE TUBB4A 1814/4885TUBB 1342/4885TUBA3C 1992/4885
US-20080254024-A1 ANTI-EPHB2 ANTIBODIES AND METHODS USING SAME EPHB2, EPHB3, EPHB1 TUBB4A 104/4885TUBB 61/4885TUBA3C 123/4885
US-20070092940-A1 A free cysteine amino acid is a cysteine residue which has been engineered into the parent antibody and is not part of a disulfide bridge; diagnostics and therapeutics; killing or inhibiting the proliferation of tumor cells or cancer cells LNPEP, CSTB, ALB TUBB4A 95/4885TUBB 40/4885TUBA3C 588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.